













































[USPTO PATENT FULL-TEXT AND IMAGE DATABASE](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[Bottom](#)[View Cart](#)

Searching US Patent Collection...

Results of Search in US Patent Collection db for:**AN/"IONIS PHARMACEUTICALS": 161 patents.****Hits 1 through 50 out of 161**[Next 50 Hits](#)[Jump To](#)[Refine Search](#)

PAT. NO.	Title
1	11,021,710  Compounds and methods for reducing FXI expression
2	11,000,595  Modulators of PCSK9 expression
3	10,961,271  Methods of modulating KEAP1
4	10,927,377  Modulators of APOL1 expression
5	10,927,372  Compositions and methods for modulating apolipoprotein C-III expression
6	10,912,792  Compounds and methods for modulating angiotensinogen expression
7	10,907,160  Methods for reducing LRRK2 expression
8	10,883,104  Compositions and methods for modulating apolipoprotein (a) expression
9	10,865,414  Modulators of DNMT2 expression
10	10,865,413  Oligomeric compounds comprising .alpha.-.beta.-constrained nucleic acid
11	10,858,657  Methods for treating hypercholesterolemia
12	10,851,371  Modulation of SMN expression
13	10,844,379  Conjugated antisense compounds and their use
14	10,837,016  Modulation of huntingtin expression
15	10,822,369  Compounds and methods for the modulation of proteins
16	10,815,483  Compositions for modulating C9ORF72 expression
17	10,815,480  Modulation of alpha synuclein expression
18	10,793,862  Compositions and methods for modulating growth hormone receptor expression
19	10,793,855  Compositions for modulating expression of C9ORF72 antisense transcript
20	10,774,333  Modulators of PNPLA3 expression
21	10,772,906  Modulation of Factor 11 expression
22	10,752,940  Compounds and methods for detecting oligonucleotides
23	10,751,419  Method for synthesis of reactive conjugate clusters
24	10,745,756  Methods of predicting toxicity

- 25 [RE48,060](#)  [Antisense modulation of PTP1B expression](#)
 - 26 [10,683,499](#)  [Compositions and methods for modulating TTR expression](#)
 - 27 [10,676,738](#)  [5' modified nucleosides and oligomeric compounds prepared therefrom](#)
 - 28 [10,655,129](#)  [Compositions and their uses directed to huntingtin](#)
 - 29 [10,619,158](#)  [Modulation of huntingtin expression](#)
 - 30 [10,619,157](#)  [Cancer treatment](#)
 - 31 [10,618,931](#)  [Method for solution phase detritylation of oligomeric compounds](#)
 - 32 [10,590,412](#)  [Compositions and methods for modulation nucleic acids through nonsense mediated decay](#)
 - 33 [10,577,607](#)  [Modulation of DYRK1B expression](#)
 - 34 [10,577,604](#)  [Methods for monitoring C9ORF72 expression](#)
 - 35 [10,570,169](#)  [Conjugated antisense compounds and their use](#)
 - 36 [10,557,137](#)  [Modulating apolipoprotein \(a\) expression](#)
 - 37 [10,538,763](#)  [Compounds and methods for modulation of DUX4](#)
 - 38 [10,533,178](#)  [Methods for modulating Ataxin 2 expression](#)
 - 39 [10,533,175](#)  [Compositions and methods for modulating Ataxin 3 expression](#)
 - 40 [10,526,604](#)  [Modulation of nuclear-retained RNA](#)
 - 41 [10,517,953](#)  [Modulators of PCSK9 expression](#)
 - 42 [10,517,889](#)  [Modulators of SMAD7 expression](#)
 - 43 [10,493,092](#)  [Antisense compounds](#)
 - 44 [10,479,993](#)  [Modulation of signal transducer and activator of transcription 3 \(STAT3\) expression](#)
 - 45 [10,478,449](#)  [2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations](#)
 - 46 [10,478,448](#)  [Methods and compositions for modulating apolipoprotein \(a\) expression](#)
 - 47 [10,472,634](#)  [Antisense compounds targeting apolipoprotein E receptor 2](#)
 - 48 [10,472,629](#)  [Methods and compositions for modulating apolipoprotein \(A\) expression](#)
 - 49 [10,450,342](#)  [Method for solution phase detritylation of oligomeric compounds](#)
 - 50 [10,443,052](#)  [Compositions for modulating C9ORF72 expression](#)
-

